Ivermectin: Malaria Reduction & Mosquito Control
Ivermectin Shows Notable Promise in Reducing Malaria Incidence, Offering New Hope for Control Efforts
Table of Contents
New research from the BOHEMIA project, conducted in Kenya and Mozambique, indicates that ivermectin, when administered through mass drug management (MDA), can substantially reduce malaria infection rates, particularly among children. The findings suggest a potential new tool to complement existing malaria control strategies and combat growing insecticide resistance in mosquitoes.
In a large-scale trial in Ale County, Kenya, children who received ivermectin experienced a notable 26% reduction in malaria infection incidence compared to those who received albendazole, the control drug. The study, involving over 20,000 participants and more than 56,000 treatments, demonstrated that ivermectin effectively lowered malaria infection rates. This effect was more pronounced in children living further from cluster borders or in areas with more efficient drug distribution. Crucially, ivermectin exhibited a favorable safety profile, with no severe drug-related adverse events reported. Only mild, transient side effects, consistent with those observed in campaigns against neglected tropical diseases, were noted.
“We are thrilled with these results,” stated Carlos Chaccour, co-principal investigator of the BOHEMIA project and ISGlobal researcher at the time of the study. ”Ivermectin has shown great promise in reducing malaria transmission and could complement existing control measures. With continued research, ivermectin MDA could become an effective tool for malaria control and even contribute to elimination efforts.” Chaccour,now a researcher at the Navarra Center for International Advancement at the University of Navarra,emphasized the drug’s potential.
Joseph Mwangangi from the KEMRI-Wellcome Trust Research Programme commented, “these results align with the World health Association’s (WHO) criteria for new vector control tools.” Marta Maia, BOHEMIA’s lead entomologist from the University of Oxford, added, “The findings suggest that ivermectin MDA could be a valuable complementary strategy for malaria control, particularly in areas where mosquito resistance to insecticides is a growing concern.”
Lessons from the Mozambique Trial
The implementation of the Mozambique trial in the rural district of Mopeia faced significant challenges, including disruptions from Cyclone Gombe (2022) and a subsequent cholera outbreak. These events underscored the critical importance of community engagement. “One of the most crucial lessons we learned from the trial in Mopeia is that strong community engagement is essential,” said Francisco Saúte, director of the Manhiça health Research Centre (CISM). “Building trust with local communities and fostering close collaboration with the Health Ministry, National Malaria Control Program, and local authorities was key to ensuring acceptance of the ivermectin MDA.”
Expanding the Impact Beyond Malaria
Beyond its impact on malaria transmission, ivermectin MDA offers significant collateral benefits.The BOHEMIA team observed a significant reduction in the prevalence of skin infestations like scabies and head lice in the ivermectin group in Mozambique. Communities also reported a major decrease in bed bugs in Kenya.These additional public health benefits are particularly valuable when ivermectin is integrated into existing delivery systems, maximizing its overall impact.
Shaping the Future of Malaria Prevention
This research is part of a broader global initiative to evaluate ivermectin’s potential in malaria control. The findings have been reviewed by the WHO vector control advisory group,which recognized the study’s demonstrated impact and recommended further examination. The results have also been shared with national health authorities as thay consider the inclusion of ivermectin in their malaria control programs.
“This research has the potential to shape the future of malaria prevention, particularly in endemic areas where existing tools are failing,” concluded Regina Rabinovich, BOHEMIA PI and director of ISGlobal’s Malaria Elimination Initiative. “With its novel mechanism of action and proven safety profile,ivermectin could offer a new approach using a well-known,safe drug that can add to the effect of other mosquito control tools available today.”